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Background: Taxanes are the most active chemotherapy agents in metastatic castra-
tion-resistant prostate cancer (mCRPC) patients; yet, resistance occurs almost invari-
ably, representing an important clinical challenge. Taxane-platinum combinations have
shown clinical benefit in a subset of patients, but the mechanistic basis and biomarkers
remain elusive.
Objective: To identify mechanisms and response indicators for the antitumor efficacy of
taxane-platinum combinations in mCRPC.
Design, setting, and participants: Transcriptomic data from a publicly available mCRPC
dataset of taxane-exposed and taxane-naïve patients were analyzed to identify response
indicators and emerging vulnerabilities. Functional and preclinical validation was
performed in taxane-resistant mCRPC cell lines and genetically engineered mouse
models (GEMMs).
Intervention: Metastatic CRPC cells were treated with docetaxel, cisplatin, carboplatin,
the CXCR2 antagonist SB265610, and the BCL-2 inhibitor venetoclax. Gain and loss of
function in culture of CXCR2 and BCL-2 were achieved by overexpression or siRNA
silencing. Preclinical assays in GEMM mice tested the antitumor efficacy of taxane-
platinum combinations.uted equally.
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Outcome measurements and statistical analysis: Proliferation, apoptosis, and colony
assays measured drug activity in vitro. Preclinical endpoints in mice included growth,
survival, and histopathology. Changes in CXCR2, BCL-2, and chemokines were analyzed
by reverse transcriptase quantitative polymerase chain reaction and Western blot.
Human expression data were analyzed using Gene Set Enrichment Analysis, hierarchical
clustering, and correlation studies. GraphPad Prism software and R-studio were used for
statistical and data analyses.
Results and limitations: Transcriptomic data from taxane-exposed human mCRPC
tumors correlate with a marked negative enrichment of apoptosis and inflammatory
response pathways accompanied by a marked downregulation of CXCR2 and BCL-2.
Mechanistically, we show that docetaxel inhibits CXCR2 and that BCL-2 downregulation
occurs as a downstream effect. Further, we demonstrated in experimental models that
the sensitivity to cisplatin is dependent on CXCR2 and BCL-2, and that targeting them
sensitizes prostate cancer (PC) cells to cisplatin. In vivo taxane-platinum combinations
are highly synergistic, and previous exposure to taxanes sensitizes mCRPC tumors to
second-line cisplatin treatment.
Conclusions: The hitherto unappreciated attenuation of the CXCR2/BCL-2 axis in taxane-
treated mCRPC patients is an acquired vulnerability with potential predictive activity for
platinum-based treatments.
Patient summary: A subset of patients with aggressive and therapy-resistant prostate
cancer benefits from taxane-platinum combination chemotherapy; however, we lack the
mechanistic understanding of how that synergistic effect occurs. Here, using patient data
and preclinical models, we found that taxanes reduce cancer cell escape mechanisms to
chemotherapy-induced cell death, hence making these cells more vulnerable to addi-
tional platinum treatment.
© 2020 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).
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Despite significant initial responses to androgen depriva-
tion therapy, most metastatic patients progress to an
incurable castration-resistant prostate cancer (mCRPC)
[1,2]. Many drugs have been approved for the treatment
of mCRPC, including taxanes, and androgen receptor (AR)
signaling inhibitors [2,3]. Sadly, in patients progressing to
these agents, very few therapeutic options are available,
although platinum-based treatments have demonstrated a
limited benefit in patients with aggressive variant prostate
cancer (PC) [4–6]. Predictive markers are needed to
determine the best treatment for patients previously
treated with taxanes or AR signaling inhibitors.
Taxanes bind tubulin-inhibiting mitosis but also AR
nuclear translocation, reducing AR signaling [7–9]. Several
factors are associated with taxane resistance, including
expression of b-tubulin isoforms and activation of drug
efflux pumps. PTEN loss and activation of PI3K/AKT/mTOR,
MAPK, and NF-kB have also been associated with taxane
resistance [10,11]. While platinum agents are not used
routinely for the treatment of mCRPC, there is an increasing
use of these agents, especially in patients with small-cell or
neuroendocrine tumor variants [6]. In fact, some antitumor
activity has been described for carboplatin, cisplatin, and
satraplatin in mCRPC patients [12]. Unfortunately, molecu-
lar biomarkers to identify mCRPC patients who could
benefit from these drug combinations remain elusive. The
incomplete understanding of the molecular mechanisms of
taxane resistance limits the identification of vulnerabilities
and potential therapeutic targets.
Here, we sought to elucidate the mechanistic basis and
response indicators for the synergistic antitumor efficacy oftaxane-platinum combinations in advanced PC (Supplemen-
tary Fig. 1). Mining of human PC datasets to compare the
transcriptomes of taxane-exposed and taxane-naïve patients
showed a marked downregulation of CXCR2 and BCL-2 in
taxane-exposed patients. Mechanistically, we showed that
taxanes induce CXCR2 and BCL-2 downregulation. Further, we
demonstrated that CXCR2 and BCL-2 determine cisplatin
sensitivity and that targeting them sensitizes PC cells to
cisplatin. Finally, in vivo preclinical data testing show that
taxane-platinum combinations are highly synergistic and that
previous exposure to taxanes sensitizes mCRPC tumors to
cisplatin. Together, our data identify an acquired vulnerability
in taxane-treated mCRPC patients with a potential predictive
value for platinum-based drug combinations.
2. Materials and methods
See the Supplementary material for further detail.
2.1. Computational analysis of human PC data
Human transcriptome data [13,14] were used for gene expression
(Supplementary Table 1) and pathway enrichment using Gene Set
Enrichment Analysis (GSEA; Supplementary Table 2). Univariate analyses
were performed using Spearman rank correlation tests. For bivariate
analysis, linear regressions were performed (Supplementary Table 3).
False discovery rate and bootstrapping were performed when appropri-
ate, to correct for multiple testing.
2.2. Functional assays in vitro
Docetaxel-resistant DU145-DR and PC3-DR human PC cells had been
generated previously [15]. Docetaxel, cabazitaxel, cisplatin, carboplatin
(MedChemExpress; Monmouth Junction, NJ, USA), CXCR2 antagonist
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venetoclax (MedChemExpress; Monmouth Junction, NJ, USA) were
prepared in dimethyl sulfoxide. Western blot, cell viability, apoptosis,
and gain and loss of function studies were performed as described
previously [16]. Oligonucleotides and antibodies are listed in Supple-
mentary Table 4.
2.3. Preclinical assays in vivo
Animal studies were approved by the Institutional Review Board at
IDIBELL. The NPK mouse model had been published previously [17]. For
tumor growth and survival assays, allografted NPK tumor-bearing mice
were enrolled in preclinical studies.
2.4. Immunohistochemical analysis
Immunostaining of mouse prostate tumor tissues was performed, as
described previously [18], on formalin-fixed paraffin-embedded sections
incubated with primary and secondary antibodies shown in Supple-
mentary Table 4.
2.5. Statistical analysis
Statistical differences were calculated using nonlineal regression and F
test for viability, or two-tailed Student t test for clonogenicity and
apoptosis; p < 0.05 was considered significant. One-way analysis of
variance was used for vehicle and each treatment group in in vivo
preclinical assays. In survival analysis, p values were calculated using a
log-rank test. Radiographic progression was defined using Response
Evaluation Criteria in Solid Tumors version 1.1. A decline in prostate-
specific antigen (PSA) was evaluated according to Prostate Cancer
Clinical Trials Working Group 3 (PCWG3) guidelines (PSA decline  50%)
to the date of radiographic progression of disease. Radiographic
progression-free survival was estimated by the Kaplan-Meier method
and compared using the log-rank or Fisher exact test. PSA decline was
evaluated using Fisher exact test, with a significance level of 5% used to
measure the association with PSA decline.
3. Results
3.1. The CXCR2/BCL-2 axis is attenuated in human PC exposed
to taxane
We investigated the transcriptomic changes in mCRPC
tumors exposed to taxanes in a human PC dataset [13]. GSEA
identified significantly enriched hallmark cancer pathways
(Supplementary Fig. 2A and Supplementary Table 2)
including “androgen response” (normalized enrichment
score [NES] = 2.002; false discovery rate [FDR] q
value = 8.16  105). Interestingly, “apoptosis” (NES = –
1.817; FDR q value = 5.76  104) and “inflammatory
response” (NES = –1.933964; FDR q value = 2.05  104)
pathways were enriched negatively in taxane-exposed
mCRPC tumors (Fig. 1A and B), prompting us to hypothesize
a role in platinum treatment response, as we showed
previously in other tumor types [16]. A comparison of gene
expression changes between the significantly enriched
pathways showed only the “interferon alpha and gamma”
pathways as marginally differentially expressed compared
with “apoptosis” and “inflammatory response”
(p = 0.017 and p = 0.038, respectively; Fig. 1C). Moreover,the mean expression was significantly lower than that of a
random model equally sized to the top differentially
expressed genes (p < 0.001) between taxane-naïve and
taxane-exposed tumors, and similar to that of a multigene
signature using all genes in the leading edge of the
significantly enriched pathways (Supplementary Fig. 2B).
Unsupervised clustering of the GSEA leading-edge genes
from the “apoptosis” significantly segregated patients ex-
posed to taxanes in the SU2C dataset (p = 0.004; Fig. 1D).
Significantly downregulated genes included the antiapoptotic
master regulator BCL-2 (p = 0.007), as well as CXCL8
(p = 0.043) and CXCL6 (p = 0.007; Supplementary Table 1),
known to bind the CXCR2 receptor and trigger antiapoptosis
programs [19]. In fact, CXCR2 and BCL-2 expression levels are
significantly correlated with the negative enrichment of the
“apoptosis” pathway in taxane-exposed patients but not in
taxane-naïve ones (p = 0.04 and p = 0.030, respectively; Fig.1E
and Supplementary Table 3), and are associated with
decreased AR and increased neuroendocrine PC scores
(Supplementary Fig. 2C and D). Moreover, CXCR2 and BCL-2
mRNA levels were found significantly downregulated
(p = 0.042 and p = 0.001, respectively) in an independent
human dataset (Fig.1F) [14]. Together, these data indicate that
taxane treatment attenuates the antiapoptotic signaling
mediated by CXCR2 and BCL-2 in mCRPC patients.
3.2. Docetaxel induces CXCR2/BCL-2 downregulation in vitro
and in vivo
We next asked whether CXCR2/BCL-2 downregulation
was causally linked to taxane exposure. We observed an
immediate downregulation of CXCR2 and BCL-2 in doc-
etaxel-treated DU145 and PC3 cells (Fig. 2A). In agreement
with the in vitro observation, tumors from the docetaxel-
treated NPK mice showed a marked reduction in CXCR2 and
BCL-2 compared with nontreated controls (Fig. 2B). Impor-
tantly, this downregulation of CXCR2 and BCL-2 upon taxane
exposure was also observed in p53-proficient LNCaP cells
(Supplementary Fig. 3I).
Next, we evaluated CXCR2 and BCL-2 levels in docetaxel-
resistant cell derivatives, namely, DU145-DR and PC3-DR
(Supplementary Fig. 3A). Consistently, protein levels of
CXCR2 and BCL-2 in untreated DU145-DR and PC3-DR cells
were reduced profoundly (Fig. 2C). In addition, CXCR2
ligands CXCL8 and CXCL6 were also significantly down-
regulated (Supplementary Fig. 3B), as was CXCR1, which is
coregulated with CXCR2 (Supplementary Fig. 3C) [20]. No-
tably, reduced CXCR2 expression was not due to promoter
hypermethylation, as treatment with the 5-AZA did not
increase protein expression (Supplementary Fig. 3C and D).
Depletion of CXCR2 or CXCL8/CXCL6 has been shown to
promote BCL-2 downregulation in different tumor types
[16,21,22]. In fact, silencing of CXCR2 in parental DU145 and
PC3 cells (Supplementary Fig. 3E) induced a marked
reduction in BCL-2 protein expression compared with
control cells (Fig. 2D). Additionally, DU145-DR cells, which
are depleted of CXCR2, were four-fold more resistant to
CXCR2 inhibitor SB265610 than parental cells (p < 0.0001;
Fig. 2E). Conversely, CXCR2 overexpression significantly
Fig. 1 – CXCR2 and BCL-2 are downregulated in human prostate cancer exposed to taxane. GSEA showing a significant negative enrichment for the (A)
apoptosis and (B) inflammatory response pathways from the hallmarks pathways of the MSigDB in the differential gene expression signature of the
taxane-naïve versus taxane-exposed tumors in the SU2C dataset. (C) Density plots show the difference in the median gene expression change between
the apoptosis and inflammatory response pathways (control) and between these two pathways and each of the top significantly enriched (by GSEA)
pathways using nonparametric Kruskal-Wallis test. (D) Unsupervised clustering of patients according to the gene expression of the leading-edge genes
from the GSEA in (B). The Fisher exact t test p value for the association of taxane-exposed status and downregulation of the signature are shown in
the heatmap. (E) Linear regressions for the correlation between CXCR2 (left) and BCL-2 (right) expression and the normalized enrichment score of the
apoptosis pathway. Taxane-exposed and taxane-naïve patients are shown separately. The p value indicates the significance of the differential
association between gene expression and pathway enrichment using t test. (F) Differences in mRNA expression between taxane-exposed and taxane-
naïve patients in the FHCRC dataset for CXCR2 (left) and BCL-2 (right) using t test. Control for multiple testing was performed using false discovery
rate adjustment on differential expression, pathway enrichment, and bootstrapping for correlation analysis. ES = enrichment score; FC = fold change;
FDR = false discovery rate; GSEA = Gene Set Enrichment Analysis; LN = lymph node; NA = not available; NES = normalized enrichment score.
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G, and Supplementary Fig. 3F). Similarly, BCL-2 over-
expression in DU145-DR and PC3-DR cells (Supplementary
Fig. 3G) resulted in a significant change in docetaxelsensitivity (p = 0.012 and p < 0.0001, respectively; Fig. 2H
and I), apoptosis (p = 0.040 and p = 0.021, respectively;
Fig. 2J and K), and clonogenicity (p = 0.021 in PC3-DR cells;
Fig. 2L and M).
Fig. 2 – Effect of docetaxel treatment on CXCR2/BCL-2 axis regulation. (A) Representative Western blot images (n = 3) showing protein expression changes
of CXCR2 and BCL-2 in DU145 and PC-3 cells after treatment with docetaxel (Doce) at 6.5 and 15 nM, respectively, for 72 h; a-tubulin was used as an
endogenous control. (B) Experimental strategy: 1 mo after tamoxifen-mediated induction of the cre-dependent, recombination, tumor-bearing mice (n = 4)
were exposed to four cycles of docetaxel treatment (oral gavage, 2 mg/kg, Monday to Friday) or vehicle (top). Western blot showing CXCR2 and BCL-2
protein expression changes in tumor tissues from NPK GEMM exposed to docetaxel or vehicle; a-tubulin was used as an endogenous control (bottom). (C)
Experimental strategy: DU145 and PC3 cells were converted to docetaxel-resistant cells by exposing them to increasing doses of docetaxel in an
intermittent regimen during 1 yr and 6 mo, respectively (top). Western blot analysis (n = 3) of CXCR2 and BCL-2 basal protein expression in PC3/PC3-DR and
DU145/DU145-DR cell lines; a-tubulin was used as an endogenous control (bottom). (D) Representative western blot images (n = 3) showing changes in
CXCR2 and BCL-2 protein expression in PC3 and DU145 cells under negative control (siCtrl) and CXCR2 (siCXCR2) gene silencing; a-tubulin was used as an
endogenous control. (E) Dose-response curves for DU145 and DU145-DR cells after SB265610 treatment at 0–100 mM for 72 h (mean  SEM). (F) Western
blot analysis (n = 3) of CXCR2 and BCL-2 protein expression changes under empty control (Crtl) and CXCR2 overexpression (CXCR2ov) in PC3-DR cells;
a-tubulin was used as and endogenous control. (G) Dose-response curves for PC3-DR cell line, after CXCR2ov, treated with 0–50 nM docetaxel for 72 h
(mean  SEM). Dose-response curves for (H) DU145-DR and (I) PC3-DR cell lines, after BCL-2 overexpression (BCL-2ov), treated with 0–50 nM docetaxel for
72 h. Bar graph representing the percentage (mean  SEM) of late apoptotic cells after 72 h of treatment with docetaxel in (J) DU145-DR (5 nM) and (K) PC3-
DR (15 nM) after BCL-2ov. The p value was relative to cells transfected with an empty vector (Empty Ctrl) treated with docetaxel. (L) Representative colony
assay images after treatment with docetaxel at 0.5 nM for 72 h in DU145-DR and PC3-DR cells, after BCL-2ov. (M) Bar graph representing the percentage
(mean  SEM) of colonies after 72 h of treatment with docetaxel in DU145-DR (left) and PC3-DR (right) after BCL-2ov. The p value was relative to cells
transfected with an empty vector (Empty Ctrl) treated with docetaxel. Results were obtained from at least three independent biological replicates. The p
values were calculated using nonlineal regression and F test for viability, or two-tailed Student t test for clonogenicity and apoptosis, and considered
significant when <0.05. IC50 = half maximal inhibitory concentration; SEM = standard error of the mean.
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induces a downregulation of CXCR2 and BCL-2, in vitro and
in vivo, and that this downregulation is maintained after
docetaxel resistance is established.3.3. Downregulation of CXCR2/BCL-2 sensitizes PC cells to platinum
Inhibition of CXCR2 signaling and its downstream effector
BCL-2 increases the sensitivity of tumor cells to platinum
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docetaxel triggers a marked reduction in the CXCR2/BCL-
2 axis, and the clinical benefit observed for the combination
of platinum and taxanes in mCRPC [24], we hypothesized
that the sensitivity of docetaxel-resistant PC cells to
platinum treatment might be CXCR2/BCL-2 dependent. As
predicted, docetaxel-resistant DU145-DR and PC3-DR cells
were significantly more sensitive to cisplatin and carbo-
platin than their respective parental cells (DU145-DR,
p = 0.004 and p < 0.0001; PC3-DR p < 0.0001 and
p < 0.0001 for cisplatin and carboplatin, respectively;
Fig. 3A and B). In agreement with the observed down-
regulation of antiapoptotic signaling in the taxane-treated
patients of the SU2C human PC cohort, cisplatin induced a
significant dose-dependent increase in late apoptosis rates
in the docetaxel-resistant DU145-DR cells, as compared
with parental DU145 cell line (p = 0.041 and p = 0.019 for
2.5 and 5 mM of cisplatin, respectively; Fig. 3C and D, and
Supplementary Fig. 3K and L), which was also confirmed in
clonogenic assays (Fig. 3E–G).
To ascertain the role of CXCR2 and BCL-2 in cisplatin
sensitivity, we silenced them and assessed the cytotoxicity
of cisplatin. Silencing of CXCR2 (Fig. 2D and Supplementary
Fig. 3E) showed significantly enhanced sensitivity for
cisplatin compared with nontargeting siRNA control
DU145 and PC3 cells (p < 0.0001 and p < 0.0001, respec-
tively; Fig. 4A). Similar results were found when BCL-2 was
silenced (p = 0.016 and p = 0.0005, respectively; Fig. 4B
and Supplementary Fig. 3H). Importantly, treatment of
docetaxel-sensitive DU145 cells with the CXCR2 inhibitor
SB265610 significantly sensitized cells to cisplatin in cell
viability (Fig. 4C and D) and clonogenic assays (Fig. 4E),
which was confirmed in p53-proficient LNCaP cells
(Supplementary Fig. 3J). Similarly, treatment of DU145 or
PC3 cells with the BCL-2 inhibitor venetoclax enhanced
cisplatin sensitivity significantly (p = 0.023 and p < 0.001,
respectively; Fig. 4F and G).
Conversely, overexpression of CXCR2 cells resulted in a
significant reduction in cisplatin sensitivity (p < 0.0001), an
increase in clonogenic capacity (p = 0.042), and reduced
apoptosis (p = 0.005; Fig. 4H and J). This was also observed
upon BCL-2 overexpression in either DU145-DR or PC3-DR
cells (p < 0.0001 and p < 0.0001, respectively; Fig. 4K)
together with resistance to clonogenic inhibition (-
p = 0.048 and p = 0.002, respectively; Fig. 4L and M) and a
dose-dependent reduction in apoptosis (Fig. 4N and O).
Taken together, these data indicate that docetaxel-
resistant PC cells are more sensitive to cisplatin treatment
and suggest that this vulnerability is in part mediated by the
downregulation of the CXCR2/BCL-2 signaling.
3.4. Taxane treatment sensitizes a mouse CRPC model to
cisplatin treatment
To test the hypothesis that platinum added to taxane may
improve survival and response in aggressive mCRPC, we
conducted “preclinical assay 1” in allografted NPK PC
models (Fig. 5A). No significant reduction in tumor growth
was observed in mice treated with docetaxel, cabazitaxel, orcisplatin alone (Fig. 4B), albeit a modest improvement in
survival of mice treated with docetaxel (median survival
65  4.9 vs 55.5  4 d, p < 0.001) and cabazitaxel
(61  3.14 vs 55.5  4 d, p = 0.006), but not with cisplatin
(56  1.7 vs 55.5  4 d, p = 0.3; Fig. 4D). Comparable results
in tumor growth inhibition were found with carboplatin
(Supplementary Fig. 4A). Treatments were well tolerated in
vivo, and no signs of toxicity were identified at the indicated
doses (Supplementary Fig. 4B). Importantly, a significant
reduction in tumor growth was observed in docetaxel- or
cabazitaxel-cisplatin combinations (p = 0.0111 and
p = 0.007, respectively) and a remarkable improvement in
survival (two of 10 reaching endpoint in docetaxel
+ cisplatin: median survival 75  2.2 vs 55.5  4 d,
p = 1.2  1010; none reaching endpoint in cabazitaxel
+ cisplatin: median survival 75  0 vs 55.5  4 d,
p = 6.8  1012; Fig. 5B–D).
We next asked whether previous exposure to taxane
sensitizes otherwise resistant tumors to cisplatin treat-
ment. We engrafted mice with control, docetaxel-treated,
and cabazitaxel-treated NPK tumors from “preclinical assay
1,” and treated them with cisplatin in “preclinical assay 2”
(Fig. 5C). Notably, sequential cisplatin after docetaxel
or cabazitaxel reduced tumor growth significantly
(p = 0.038 and p = 0.029, respectively) and improved
survival (three of 10 reaching endpoint in cisplatin after
docetaxel: median survival 40.5  5.5 vs 32.5  2.3 d,
p = 0.00491; five of 10 reaching endpoint in cisplatin after
cabazitaxel: median survival 40.5  4.8 vs 32.5  2.3 d,
p = 0.0019; Fig. 5E).
We next interrogated a unique retrospective cohort of
mCRPC patients who had undergone platinum-based
treatment, namely, the Beltran dataset [25]. First, we used
the SU2C dataset to stratify patients in high versus low
expression of markers. Given the high significant correla-
tion between BCL-2 and CXCR2 expression (Supplementary
Fig. 4C) and wide range of gene expression, we used BCL-2 z
scores to define the high and low expression groups
(z scores < 0.5 as low BCL-2 and z scores > 0.5 as high
BCL-2; Supplementary Fig. 4D and E). Interrogation of the
Beltran dataset showed a clear trend toward better
radiographic progression-free survival in patients with
low BCL-2 expression than in patients with high expression
(hazard ratio = 3.41, 95% confidence interval 0.74–15.67,
p = 0.09; Fig. 5F) together with improved PSA responses
among the CRPC adenocarcinoma patients (n = 8, p = 0.07;
Fig. 5G). Interestingly, despite this trend not being found
using CXCR2 expression alone, the combined use of CXCR2
and BCL-2 showed the best trend (p = 0.059; Supplementary
Fig. 4F and G).
Analysis of tumor specimens (Fig. 6A and D, and
Supplementary Fig. 5A–C) confirmed that the improved
antitumor activity of the platinum-based combinations
compared with single taxane was associated with a
significant reduction of cell proliferation (p = 0.0027 and
p = 0.0012 for docetaxel and cabazitaxel, respectively;
Fig. 6B) and antiapoptotic BCL-2 (p = 0.019 and p = 0.010,
respectively) and CXCR2 (Fig. 6C and Supplementary
Fig. 5A), together with a marked increase in apoptosis
Fig. 3 – Docetaxel-resistant cells are more sensitive to platinum treatment. (A) Dose-response curves for DU145/DU145-DR and PC3/PC3-DR cells after
cisplatin treatment at 0–50 mM or carboplatin treatment at 0–75 mM for 72 h (mean  SEM). (B) Table showing cisplatin and carboplatin IC50 values
indicated as mean (95% CI) in PC3/PC3-DR and DU145/DU145-DR cell lines. (C) Representative images of apoptosis activation after 72 h of cisplatin
treatment of DU145 and DU145-DR cells. (D) Bar graph representing the percentage (mean  SEM) of late apoptotic cells after 72 h of treatment with
cisplatin in DU145 and DU145-DR cell lines at their corresponding IC50 doses—2.5 and 5 mM, respectively; p values were relative to parental DU145
cells. (E) Representative colony assay images after treatment with cisplatin or carboplatin at the indicated doses for 24 h in DU145/DU145-DR and PC3/
PC3-DR cells. Bar graphs representing the percentage (mean  SEM) of colonies after 24 h of treatment with cisplatin or carboplatin at the indicated
doses in (F) DU145/DU145-DR and (G) PC3/PC3DR cells; p values were relative to parental cells treated with cisplatin or carboplatin. Results shown were
obtained from at least three independent biological replicates. The p values were calculated using nonlineal regression and F test for viability, or two-
tailed Student t test for clonogenic and apoptosis, and considered significant when <0.05. CI = confidence interval; IC50 = half maximal inhibitory
concentration; RI = Resistance Index, calculated as the ratio between IC50 of resistant sublines and its corresponding sensitive cell lines;
SEM = standard error of the mean.
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AR (p < 0.001 and p = 0.006, respectively) in combination
treatments (Fig. 6F). Notably, sequential cisplatin after
taxane also showed a marked reduction in proliferation and
antiapoptotic BCL-2 (Supplementary Fig. 5B).Taken together, these data strongly suggest that the
attenuation of the CXCR2/BCL-2 axis represents a vulnera-
bility in a subset of advanced PC patients and a potential
predictive determinant of response to platinum-based
chemotherapy that needs to be validated prospectively.
Fig. 4 – Effect of CXCR2 and BCL-2 downregulation and overexpression on platinum sensitivity in PC cells. (A) Dose-response curves for PC3 and DU145
cell lines, after CXCR2 gene silencing (siCXCR2), treated with 0–50 mM cisplatin for 72 h (mean  SEM). (B) Dose-response curves for PC3 and DU145 cell
lines, after BCL-2 gene silencing (siBCL-2), treated with 0–50 mM cisplatin for 72 h (mean  SEM). (C) Bar graphs representing mean  SEM percentage
of cell viability after 72-h treatment with cisplatin, SB265610, or their concomitant combination at the indicated doses in DU145 cells; p values were
relative to cisplatin alone. (D) Dot plot representing combination index values calculated for each combined treatment dose. (E) Representative colony
assay images (left) and bar graph (right) representing the percentage (mean  SEM) of colonies in DU145 cells after treatment with cisplatin, SB265610,
or their combination at the indicated doses; p value was relative to cisplatin alone. (F) Representative colony assay images (left) and bar graph (right)
representing the percentage (mean  SEM) of colonies in DU145 cells after treatment with cisplatin, venetoclax, or their combination at the indicated
doses; p value was relative to cisplatin alone. (G) Representative colony assay images (left) and bar graph (right) representing the percentage
(mean  SEM) of colonies in PC3 cells after treatment with cisplatin, venetoclax, or their combination at the indicated doses; p value was relative to
cisplatin alone. (H) Dose-response curves for PC3-DR cells, after CXCR2 overexpression (CXCR2ov), treated with 0–50 mM cisplatin for 72 h
(mean  SEM). (I) Representative colony assay images (left) and bar graph (right) representing the percentage (mean  SEM) of colonies in PC3-DR
cells, after CXCR2ov, treated with cisplatin at 0.25 mM for 24 h; p value was relative to empty control (Ctrl) treated with cisplatin. (J) Bar graph
representing the percentage (mean  SEM) of late apoptotic cells after 72 h of treatment with 10 mM cisplatin in PC3-DR cells after CXCR2ov; p value
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Fig. 5 – Preclinical validation. (A) Scheme of the preclinical assays carried out. Preclinical assay 1 assessed the antitumor efficacy of the single agent
docetaxel, cabazitaxel, or cisplatin versus docetaxel plus cisplatin or cabazitaxel plus cisplatin. Single agent–treated tumors from preclinical assay
1 were shifted to cisplatin to test whether previous taxane exposure would sensitize for cisplatin treatment. (B) Tumor growth curves for NPK
allografts treated with the indicated drugs or vehicle for 75 d. ANOVA is used to assess the significance of the differences in tumor growth; p values
were relative to vehicle condition. (C) Tumor growth curves for single agent docetaxel- or cabazitaxel-treated, or vehicle-treated tumors from (B)
under cisplatin treatment for 45 d. ANOVA is used to assess the significance of the differences in tumor growth; p values were relative to pretreated
tumors with vehicle in (B). Kaplan-Meier survival curves for mice enrolled in (D) preclinical assay 1 or (E) preclinical assay 2. (F) Kaplan-Meier analysis
for radiographic progression-free survival on platinum-based chemotherapy-treated patients in the Beltran dataset according to their BCL-2 expression
by RNAseq (n = 21). Curves where compared using the log-rank test, with p value considered significant when <0.05. (G) Waterfall plot (n = 8) showing
the magnitude of PSA decline in the subset of mCRPC adenocarcinomas within the cohort according to their BCL-2 expression. Fisher exact test with a
significance level of 5% was used to measure the association between Bcl2 expression and PSA decline. ANOVA = analysis of variance; CI = confidence
interval; CRPC = castration-resistant prostate cancer; HR = hazard ratio; mCRPC = metastatic castration-resistant prostate cancer; PFS = progression-free
survival; PSA = prostate-specific antigen.
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Taxane-platinum combinations have shown clinical benefit
for a subgroup of mCRPC patients [6], highlighting the need
for predictive response indicators. Exploiting publicly
available datasets, we have found that in taxane-exposedwas relative to empty Ctrl cells treated with cisplatin. (K) Dose-response curve
overexpression (BCL2ov), treated with 0–50 mM cisplatin for 72 h (mean  SEM
at 0.25 mM for 24 h in DU145-DR and PC3-DR cells, after BCL-2ov. (M) Bar grap
treatment with cisplatin after BCL-2ov; p values were relative to BCL-2ov cells 
expression changes after cisplatin treatment at the indicated doses in DU145-D
endogenous control. (O) Bar graph illustrating relative protein expression leve
DU145-DR cells. All results were obtained from at least three independent biol
and F test for viability, or two-tailed Student t test for clonogenic and apoptos
concentration; PC = prostate cancer; SEM = standard error of the mean; siContrPC tumors, apoptosis and inflammatory response pathways
are dysregulated and that the CXCR2/BCL-2 axis is reduced
markedly. In vitro and in vivo assays showed that the loss of
CXCR2 and BCL-2 represents an emerging vulnerability to
genotoxic platinum-based treatments. Accordingly, inter-
rogation of a cohort of platinum-treated mCRPC patientss for DU145-DR (top) and PC3-DR (bottom) cells, after BCL-2
). (L) Representative colony assay images after treatment with cisplatin
hs representing the percentage (mean  SEM) of colonies after 24 h of
treated with cisplatin. (N) Western blot analysis of cleaved PARP protein
R cells under empty Ctrl and BCL-2 overexpression. b-actin was used as
ls of cleaved PARP after cisplatin treatment at the indicated doses in
ogical replicates. The p values were calculated using nonlineal regression
is, and considered significant when <0.05. IC50 = half maximal inhibitory
ol = cells transfected with a silencer negative transcription control.
Fig. 6 – Histopathological analysis of preclinical cohorts. (A) Hematoxylin-eosin staining with immunohistochemistry for AR and Ki-67 in tumors from
preclinical assay 1. Microphotogaphs are shown at 400T magnification and representative of five different mouse tumors. Insets correspond to 63T
magnification. Quantification of (B) Ki-67 and (C) BCL-2. (D) Representative immunohistochemistry and immunofluorescence microphotographs for
BCL-2 and cleaved PARP. Quantification of (E) cleaved PARP staining and (F) nuclear AR. Shown is the percent of positive nuclear stain over total
number of cells in five different 40T magnifications fields from at least three independent mouse tumors; p values were relative to docetaxel or
cabazitaxel treatment alone. The p values were calculated using two-tailed Student t test and considered significant when <0.05. AR = androgen
receptor; Caba = cabazitaxel; Cis = cisplatin; Doc = docetaxel; H&E = hematoxylin and eosin; Veh = vehicle.
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Finally, in agreement with other studies [26], our preclinical
trials in vivo confirm that taxane exposure sensitizes PC
cells to platinum.
In addition to stabilizing microtubules, taxanes induce
apoptosis by inhibiting antiapoptotic proteins, such as BCL-2
[27]. Accordingly, following treatment with paclitaxel, BCL-2
is phosphorylated in PC3 and LNCaP cells, inhibiting its
antiapoptotic action and enhancing cell death [28,29]. Consis-
tent with our results, BCL-2 downregulation after docetaxel
treatment has been shown in breast cancer cells [30]. Down-
regulation of a drug's target and signaling rewiring to elicitprosurvival pathways is a well-known mechanism of cancer
treatment resistance [31]. Therefore, our data suggest that
mCRPC patients lose BCL-2 expression, at least in part,
through CXCR2 downregulation as a mechanism to evade
docetaxel-induced apoptosis. In agreement with previous
data [16,22,23], we demonstrated that inhibition of the CXCR2
chemokine receptor markedly increased the sensitivity of AR-
dependent and AR-independent PC cells to cisplatin treat-
ment, suggesting that the inverse relationship between
docetaxel resistance and cisplatin resistance could be
mediated, at least in part, by CXCR2 downregulation after
taxane exposure. Conversely, other studies also demonstrated
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become sensitive to taxanes [32,33].
In line with the findings from a recent phase I/II trial [24],
our in vivo preclinical results in an AR-indifferent PC model
suggest that therapeutic responses to cisplatin-based
chemotherapy in docetaxel-resistant mCRPC patients might
be predicted by CXCR2/BCL-2 expression. While we show
that taxane consistently reduces CXCR2 and BCL2, only a
subset of patients is expected to respond to taxane-
platinum combinations, likely reflecting the inherent
limitation of preclinical models in recapitulating the
spectrum of heterogeneity. Finally, clinical qualification of
CXCR2 and/or BCL-2 as a predictive biomarker will first
require determining the most suitable analytical test and
biospecimen. Our data using transcriptomics from the SU2C
cohort to define expression thresholds subsequently used in
the retrospective Beltran dataset illustrate the feasibility of
this general approach to estimate the subset of patients
expected to benefit from platinum-based combinations.
Ultimately, cutoff thresholds to classify patients as those
having low or high BCL-2 or CXCR2 expression and their
association to treatment response will need to be tested and
validated in independent prospective trials.
5. Conclusions
The CXCR2/BCL-2 antiapoptotic axis is markedly reduced in
taxane-exposed mCRPC tumors, representing an emerging
vulnerability to genotoxic platinum-based treatments.
Therefore, taxane-resistant tumors are sensitized to cis-
platin treatment, and taxane-cisplatin combinations have
antitumor efficacy in aggressive mCRPC. Our findings also
suggest that CXCR2/BCL-2 expression levels might predict
therapeutic response to cisplatin-based treatment in
docetaxel-resistant mCRPC patients.
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